Ask about Tesamorelin
Get a grounded answer across clinical evidence, community patterns, and risks.
Tesamorelin
Also known as: Egrifta
Growth hormone-releasing hormone (GHRH) analog
Mechanism of Action
Stimulates pituitary release of growth hormone, reducing visceral adipose tissue.
Note: HIV-associated lipodystrophy only
Tesamorelin is one of the few peptides with actual FDA approval — for HIV-associated lipodystrophy — yet observational data suggests substantial off-label interest for body composition and GH optimization. Clinical effect scores reach 95/100 for both body composition (14 trials) and growth hormone outcomes. Self-reported data from 42 unique individuals highlights body composition as the top focus area.
Reported Outcomes
Clinical grade reflects published research; Community grade reflects user reports (n=1,248).
Effects on growth hormone levels
As a GHRH analog, Tesamorelin robustly increases endogenous pulsatile growth hormone secretion and significantly elevates circulating IGF-1 levels.
Changes in muscle vs fat ratio
Tesamorelin consistently reduces visceral adipose tissue (VAT) significantly in multiple clinical trials while preserving or increasing muscle area and density. It is FDA-approved for reducing abdominal fat in HIV-associated lipodystrophy.
Effects on sleep quality
Effects on mood and cognitive function
In older adults and those with mild cognitive impairment, Tesamorelin increased brain GABA levels and improved cognitive function in a randomized trial.
Changes in energy and fatigue levels
Improvements in mitochondrial function, assessed by phosphocreatine recovery, were observed and correlated with increases in IGF-1 levels.
Muscle recovery and repair from exercise or injury
Who Discusses Tesamorelin
From community reports with demographic data.
Gender
n=107
Age Distribution (limited data)
n=48
Side Effects
Limited dataBased on 7 user reports (n=7). Frequency indicates how often each was mentioned.
Uncommon (1-5%)
Risks & Warnings
Important safety considerations based on clinical data and community reports.
Carpal Tunnel
May occur with elevated GH levels. Usually resolves with dose adjustment.
Water Retention
Fluid retention can occur with GH-releasing peptides. Usually mild and temporary.
Injection Site Reactions
Local reactions are common and usually mild. Rotate injection sites.
Dosing
Standard Protocol
- Starting Dose
- 2mg daily
- Titration
- Fixed dose
- Half-life
- 26-38 minutes
- Administration
- Subcutaneous injection, once daily
- FDA-Approved Doses
- 2mg
Community Dosing Patterns
Based on 182 mentions
Community-reported patterns, not medical advice.
Pricing
Research-grade reference pricing for 10mg vial. Prices vary by vendor and quantity. Research chemicals require self-mixing and lack medical oversight. Shipping is not included.
We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.
US Research Grade
Single small vial from US domestic vendors
US Research (Bulk)
Per-dose equivalent when buying larger US vials
China Research
Per-vial when buying 10-pack from Chinese vendors
Research
Key Studies
AIDS (London, England) (2024)
The Journal of clinical endocrinology and metabolism (2011)
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012)
The Journal of clinical endocrinology and metabolism (2012)
Top Antivir Med (2024)
Commonly Stacked With
From community members' documented stacks involving Tesamorelin.
Switching Patterns
Based on 90 discussions about switching to or from Tesamorelin.
→ Switching FROM
Users who switched to Tesamorelin
← Switching TO
Users who switched from Tesamorelin